- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07540572
Een onderzoek naar de veiligheid, farmacokinetiek en preliminaire werkzaamheid van IDE574-therapie bij volwassen deelnemers met gevorderde solide tumoren
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: IDEAYA Clinical Trials
- Telefoonnummer: +1-855-433-224
- E-mail: IDEAYAClinicalTrials@ideayabio.com
Studie Locaties
-
-
K'alak'i T'bilisi
-
Batumi, K'alak'i T'bilisi, Georgië, 6000
- Werving
- High Technology Hospital MedCenter Ltd
-
Hoofdonderzoeker:
- Tamta Makharadze, MD
-
Contact:
- Mamuka Sikharulidze
- Telefoonnummer: +995 568 999 559
- E-mail: sikharulidzemamuka3@gmail.com
-
Tbilisi, K'alak'i T'bilisi, Georgië, 114
- Werving
- Pineo Medical Ecosystem
-
Contact:
- Nino Kekenadze
- Telefoonnummer: +995 593 660 940
- E-mail: Nkekenadze@pineo.ge
-
Hoofdonderzoeker:
- Mziuri Zakaraia, MD
-
Tbilisi, K'alak'i T'bilisi, Georgië, 112
- Actief, niet wervend
- LLC ARENSIA Exploratory Medicine
-
Tbilisi, K'alak'i T'bilisi, Georgië, 144
- Actief, niet wervend
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi, K'alak'i T'bilisi, Georgië, 186
- Actief, niet wervend
- LLC Caucasus Medical Centre
-
-
-
-
California
-
Santa Monica, California, Verenigde Staten, 90404-2095
- Actief, niet wervend
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06510-3206
- Werving
- Yale School of Medicine - Cedar Street
-
Hoofdonderzoeker:
- Patricia LoRusso, MD
-
Contact:
- Karen Seely
- Telefoonnummer: 203-314-3303
- E-mail: karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation, Florida, Verenigde Staten, 33322
- Werving
- Florida Clinical Trials Group
-
Hoofdonderzoeker:
- Harshad Amin, MD
-
Contact:
- Sandra Perez
- Telefoonnummer: 772-297-3057
- E-mail: perezs@floridactg.com
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322-1013
- Werving
- Winship Cancer Institute, Emory University
-
Hoofdonderzoeker:
- Shipra Gandhi, MD
-
Contact:
- Alejandra Bono
- Telefoonnummer: 404-778-0954
- E-mail: alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110-1010
- Werving
- Washington University - Siteman Cancer Center
-
Hoofdonderzoeker:
- Faisal Fa'ak, MD
-
Contact:
- Pamela Coe
- Telefoonnummer: 314-747-7569
- E-mail: mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Verenigde Staten, 08816
- Werving
- START Astera, LLC
-
Hoofdonderzoeker:
- Bruno Fang, MD
-
Contact:
- Bruno S Fang
- Telefoonnummer: 732-426-4750
- E-mail: info@startresearch.com
-
-
New York
-
Lake Success, New York, Verenigde Staten, 11042
- Werving
- START New York Long Island, LLC
-
Hoofdonderzoeker:
- Geraldine O'Sullivan Coyne, MD
-
Contact:
- Geraldine O'Sullivan Coyne
- Telefoonnummer: 363-207-5160
- E-mail: g.osullivancoyne@startresearch.com
-
New York, New York, Verenigde Staten, 10032-3729
- Actief, niet wervend
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- SCRI Oncology Partners - PPDS
-
Hoofdonderzoeker:
- Sarah Premji, MD
-
Contact:
- Connor Frost
- Telefoonnummer: 615-478-3475
- E-mail: connor.frost@scri.com
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78758
- Werving
- NEXT Texas LLC - Austin
-
Hoofdonderzoeker:
- Sheena Sahota, MD
-
Contact:
- Heather Watson
- Telefoonnummer: 737-610-5202
- E-mail: nxtaus_coordinators@nextoncology.com
-
Dallas, Texas, Verenigde Staten, 75039
- Werving
- NEXT Texas LLC - Dallas
-
Hoofdonderzoeker:
- Faran Polani, MD
-
Contact:
- Carmen Gonzalez
- Telefoonnummer: 210-580-9479
- E-mail: NXTDFW_Coordinators@nextoncology.com
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- START Dallas Fort Worth, LLC
-
Hoofdonderzoeker:
- Henry Xiong, MD
-
Contact:
- Henry Xiong
- Telefoonnummer: 682-350-3010
- E-mail: info@startresearch.com
-
Houston, Texas, Verenigde Staten, 77030-4009
- Werving
- MD Anderson Cancer Center
-
Hoofdonderzoeker:
- Timothy Yap, MD
-
Contact:
- Desirae Dufner
- Telefoonnummer: 713-524-3434
- E-mail: DDufner@mdanderson.org
-
Houston, Texas, Verenigde Staten, 77054
- Werving
- NEXT Texas LLC - Houston
-
Hoofdonderzoeker:
- Jennifer Segar, MD
-
Contact:
- Carmen Gonzalez
- Telefoonnummer: 210-580-9479
- E-mail: nxthou_coordinators@nextoncology.com
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- NEXT Texas LLC - San Antonio
-
Hoofdonderzoeker:
- David Sommerhalder, MD
-
Contact:
- April Guerra
- Telefoonnummer: 210-580-9500
- E-mail: NXTSA_Coordinators@nextoncology.com
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- Start San Antonio, LLC
-
Hoofdonderzoeker:
- Amita Patnaik, MD
-
Contact:
- Hector Navarro
- Telefoonnummer: 210-593-5700
- E-mail: Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City, Utah, Verenigde Staten, 84119
- Werving
- START Mountain Region, LLC
-
Hoofdonderzoeker:
- William McKean, MD
-
Contact:
- William B McKean
- Telefoonnummer: 1 (801) 907-4750
- E-mail: info@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- NEXT Virginia
-
Hoofdonderzoeker:
- Mohamad Salkeni, MD
-
Contact:
- Maybelle De La Rosa
- Telefoonnummer: 703-783-4518
- E-mail: nxtvir_coordinators@nextoncology.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
Experimenteel: Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
Experimenteel: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
Experimenteel: Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Tijdsspanne: Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Tijdsspanne: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Tijdsspanne: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Tijdsspanne: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Tijdsspanne: total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Tijdsspanne: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Tijdsspanne: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Tijdsspanne: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Tijdsspanne: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Tijdsspanne: total study duration
|
total study duration
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IDE574-001
- 178299 (Andere identificatie: Regulatory Agency Identifier Number (s))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .